Document:

EXHIBIT 4.2

 

  

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT
TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

PharmaCyte Biotech, Inc. (“PharmaCyte”
or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended
(“Exchange Act”): common stock, $0.0001 par value per share (“Common Stock”). The Company’s Common Stock
has been approved for listing on The Nasdaq Stock Market LLC.

 

Description of Common Stock

 

The following is a description of the rights of
Common Stock and related provisions of the Company’s Amended Articles of Incorporation (“Articles”) and Amended Bylaws
(“Bylaws”) and applicable Nevada law. This description is qualified in its entirety by, and should be read in conjunction
with, the Articles, Bylaws and applicable Nevada law.

 

Capital Stock

 

As of July 28, 2022, our authorized capital
stock consists of 33,333,334 shares of Common Stock, of which 21,601,047 (subject to adjustment based on issuances of additional
shares as applicable due to the rounding up of fractional shares resulting from the Company’s July 12, 2021, 1:1,500 reverse
stock split) shares were issued, 20,749,066 shares were outstanding, and 10,000,000 shares of preferred stock, par value $0.0001 per
share, of which no shares were issued and outstanding.

 

Common Stock

 

Holders of our Common Stock are entitled to one
vote for each share issued and outstanding held on all matters to be voted upon by the stockholders. Our shares of Common Stock have no
preemptive, conversion, or redemption rights. The rights, preferences, and privileges of the holders of Common Stock are subject to, and
may be adversely affected by, the rights of the holders of shares of any series of preferred stock we may issue in the future. Upon the
sale of substantially all of our stock or assets or dissolution, liquidation or winding up, and after all liquidation preferences payable
to any series of preferred stock entitled thereto have been satisfied, our remaining assets shall be distributed to all holders of Common
Stock and any similarly situated stockholders who are not entitled to any liquidation preference or, if there be an insufficient amount
to pay all such stockholders, then ratably among such holders. All of our issued and outstanding shares of Common Stock are fully paid
and non-assessable. The holders of shares of our Common Stock will be entitled to such dividends and other distributions in cash, stock
or property from our assets or funds legally available for such purposes as may be declared from time to time by our board of directors
(“Board”).

 

Our Common Stock is listed on the  Nasdaq Stock
Market LLC under the symbol “PMCB”. American Stock Transfer & Trust Company LLC is the transfer agent and registrar for
our Common Stock.

 

 

 

    	 	1	 

     

    

 

Anti-Takeover Effects of Nevada Law

 

The “business combination” provisions
of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statutes (“NRS”), generally prohibit a Nevada corporation with
at least 200 stockholders of record from engaging in various “combination” transactions with any interested stockholder for
a period of two years after the date of the transaction in which the person became an interested stockholder, unless the transaction is
approved by the Board prior to the date the interested stockholder obtained such status or the combination is approved by the Board and
thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding
voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless:

 

	 	·	the combination was approved by the Board prior to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the Board before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders; or

 

	 	·	if the consideration to be paid by the interested stockholder is at least equal to the highest of: (i) the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, (ii) the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (iii) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.

 

A “combination” is generally defined
to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction
or a series of transactions, with an “interested stockholder” having: (i) an aggregate market value equal to 5% or more of
the aggregate market value of the assets of the corporation, (ii) an aggregate market value equal to 5% or more of the aggregate market
value of all outstanding shares of the corporation, (iii) 10% or more of the earning power or net income of the corporation, and (iv)
certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.

 

In general, an “interested stockholder”
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation’s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing
market price.

 

The provisions of Nevada law could have the effect
of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market
price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect
of preventing changes in the composition of our Board and management. It is possible that these provisions could make it more difficult
to accomplish transactions that stockholders may otherwise deem to be in their best interests.

 

In addition, the NRS provides for statutes, Sections
78.378 to 78.3793, inclusive, of the NRS, that limit the voting rights of the acquisition of a “controlling interest” defined
to occur at three ownership thresholds of one-fifth, one-third and a majority of the corporation’s voting power. Although our Articles
of Incorporation have not opted out of these statutes, the limitations on voting rights apply only to a corporation with 200 or more stockholders
of record, at least 100 of whom have addresses in the State of Nevada appearing on the corporation’s stock ledger during the 90
days immediately preceding the date of the acquisition.

 

 

 

 

 

 

    	 	2EXHIBIT 10.40

 

AMENDED AND RESTATED EXECUTIVE COMPENSATION
AGREEMENT

 

This Amended
and Restated Executive Compensation Agreement (“Agreement”) is entered into as of May 8, 2022, effective as of January
1, 2022 (“Amendment Date”), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors
and assigns, “Company”), and Kenneth L. Waggoner (“Executive”). The Company and the Executive are
each referred to in this Agreement as a “Party” and collectively as “Parties.”

 

RECITALS

 

WHEREAS,
the Parties wish to amend and restate the Executive Employment Compensation Agreement between them effective as of January 1, 2015, and
amended as of December 30, 2015 and March 10, 2017 (collectively, “Prior Executive Agreement”);

 

WHEREAS,
Company desires to continue to employ the Executive as the Chief Executive Officer, President and General Counsel of the Company in accordance
with the terms and conditions of this Agreement; and

 

WHEREAS,
the Executive desires to continue to serve as the Chief Executive Officer, President and General Counsel of the Company in accordance
with the terms and conditions of this Agreement.

 

NOW, THEREFORE,
in consideration of the promises, mutual covenants, the above recitals, and the agreements herein set forth, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1.     
TERM. This Agreement shall be for a term commencing on the Amendment Date and ending on the third anniversary of the Amendment
Date (such period of employment “Initial Term”), followed by automatic renewals of one (1) year thereafter (each a
“Renewal Term” and, together with the Initial Term, “Term”) unless the Company or the Executive
provides written notice of termination to the other Party at least ninety (90) days prior to the end of the Initial Term or any Renewal
Term. For the purposes hereof, the termination of this Agreement due to the Company providing written notice of termination pursuant to
this Section 1 at least ninety (90) days prior to the end of the Initial Term or any Renewal Term will be deemed to be a termination of
Executive’s employment by Company without Cause.

 

2.     
POSITION; DUTIES. The Executive shall be employed as: (i) a member of the Company’s Board of Directors (“Board”);
(ii) Chief Executive Officer, President and General Counsel of the Company; and (iii) Chief Executive Officer and General Counsel of
Viridis Biotech, Inc. and shall have the authorities and responsibilities customarily associated with the status of such positions at
Nasdaq listed biotechnology companies of the same size as the Company. In his capacity as Chief Executive Officer, the Executive shall
report directly to the Board and shall have ultimate responsibility for all the Company’s current and future operations in the
U.S. and abroad. Upon termination of the Executive’s employment for any reason, if and to the extent requested by the Company,
the Executive shall promptly resign from the Board and from all other positions that the Executive then holds with the Company or any
affiliate and promptly execute all documentation for such resignations.

 

The Executive
shall devote substantially all of his business time, effort and energies to the business of the Company; provided, however, that notwithstanding
the foregoing, the Executive may: (i) serve as an officer or director of any of the entities for whom he serves as such on the Amendment
Date or any other entity; (ii) engage in civic, charitable, public service and community activities and affairs; (iii) accept and fulfill
a reasonable number of speaking engagements; and (iv) manage his personal investments and affairs, as long as such activities do not,
in the Executive’s reasonable and good faith judgment, interfere, individually or in the aggregate, with his obligations and the
proper performance his duties and responsibilities to the Company under this Agreement in any material respect.

 

 

 

    	 	1	 

     

    

 

3.     
COMPENSATION AND BENEFITS. Subject in each case to the provisions of Section 4 of this Agreement in the event that his employment
hereunder terminates, the Executive shall be entitled to the following compensation and benefits during the Term.

 

(A)          
Base Salary. The Company will pay the Executive a base salary at an annual rate of $520,000, payable in accordance with
the Company’s usual payroll practices. The Compensation Committee of the Board may increase the base salary annually in its discretion.
The annual rate of the Executive’s base salary as in effect from time to time is referred to herein as “Base Salary.”

 

(B)           
Bonus. During the Term, the Executive shall be eligible to receive cash incentive compensation (“Bonus”)
as determined by the Board from time to time in its sole discretion. The Executive’s target annual incentive compensation shall
be fifty percent (50%) of the Executive’s Base Salary; and the Board may take into consideration the personal and Company objectives
that are set by the Board; provided, however, that such target Bonus and objectives will not limit the absolute discretion of the Board.
To earn incentive compensation, the Executive must be employed by the Company, in good standing, on the day such incentive compensation
is paid. Generally, Bonuses will be paid by March 15 of the calendar year following the year to which such Bonus pertains.

 

(C)           
Equity Compensation. During the Term, and subject to the terms and conditions of any applicable plan or other governing
documents, the Executive shall be eligible to participate in the stock option plan and restricted stock unit plan of the Company.

 

(D)           
Board Fees. The Executive will not be entitled to any cash fees or other payments or equity grants for service as a director.

 

(E)           
Expense Reimbursement. The Company will reimburse the Executive for business expenses reasonably incurred by him in the
performance of his duties with the Company, in accordance with the Company’s usual practices.

 

(F)           
Other Benefits. The Executive will be entitled to participate in the Company’s incentive and employee benefit plans
and programs applicable to senior executives generally as in effect from time to time, including medical, dental, vision and term life
insurance, and on a basis no less favorable than those provided to other senior executives. The Executive will also be entitled to participate
in the Company’s 401K plan.

 

(G)           
Vacation. The Executive will be entitled to five (5) weeks of vacation annually (or such greater amount provided in applicable
Company policies or as may be provided to any other senior executive of the Company) to be taken at times determined by the Executive;
provided, however, that unused vacation for one (1) year may be carried over to the next year if and to the extent that the unused vacation
is attributable to business exigencies of the Company. The Executive will also be entitled to two (2) weeks of paid sick leave subject
to the Company’s paid sick leave policy as in effect from time to time.

 

4.     
CONSEQUENCES OF TERMINATION. The payments under this Section 4 are the only termination payments to which the Executive is
entitled upon termination of his employment prior to the end of the Term regardless of the date during the Term in which employment is
terminated.

 

(A)          
Termination by Company for Cause or Termination by Executive without Good Reason. If the Executive’s employment under
this Agreement is terminated prior to the end of the Term by the Company for Cause (as defined below) or by the Executive without Good
Reason (as defined below), the Executive will be entitled to receive the following (promptly following such termination in the case of
clause (i)):

 

(i)             
Base Salary earned through the date that the Executive’s employment hereunder terminates (“Termination Date”);
and

 

 

 

    	 	2	 

     

    

 

(ii)           
unpaid expense reimbursements and vested amounts and benefits, if any, in accordance with the terms of any applicable plan, program,
corporate governance document, policy, agreement or arrangement of the Company other than the additional benefits provided to the Executive
under the terms of this Agreement (collectively, “Accrued Compensation”).

 

“Cause”
shall mean: a good faith determination by the Board, that any of the following has occurred: (i) willful and repeated failure by the
Executive to perform his material duties hereunder as an employee of the Company; (ii) the Executive’s conviction of, or plea of
guilty or nolo contendere to, a felony; (iii) the Executive’s theft or misuse of material Company property; (iv) willful misconduct
or an act of moral turpitude which is materially injurious to the Company, monetarily or otherwise; or (v) the Executive’s material
breach of this Agreement, including, without limitation, the confidentiality obligations set forth in Section 5 below. No termination
of the Executive’s employment will be treated as for “Cause” unless, prior to such termination, the Executive has been
provided written notice from a majority of the Board setting forth in reasonable detail the basis on which the Company is terminating
his employment for “Cause” and, if the condition is curable, the Executive will then have fifteen (15) days from receipt
of such notice during which he may remedy the condition. If full cure is made by the Executive within such fifteen (15) day cure period,
Cause shall be deemed not to have occurred and the Executive’s employment will be deemed to have continued under and subject to
the provisions of this Agreement.

 

(B)          
Termination by the Company without Cause or Termination by Executive for Good Reason. If the Executive’s employment
under this Agreement is terminated prior to the end of the Term by the Company without Cause or by the Executive for Good Reason, the
Executive will be entitled to receive the following:

 

 (i)             Accrued Compensation;

 

(ii)           
Severance equal to two times the sum of (A) the Executive’s Base Salary in effect at the time his employment terminates and
(B) the annual bonus, if any, earned by the Executive for the year preceding the year of termination, or, if greater, the target bonus,
if any, for the year of termination (collectively, “Severance Payment”);

 

(iii)          
Accelerated vesting of the unvested portion of any outstanding annual stock grant;

 

(iv)          
Accelerated vesting of the unvested portion of any outstanding additional option awards during the Term; and

 

(v)           
The amount of COBRA premiums for his and his family’s coverage, if any, under the Company’s medical and dental plans,
in effect from time to time, and shall continue to cover the Executive under the Company’s life insurance program, if any. The Executive
shall be eligible to receive such medical reimbursement and life insurance coverage until the earliest of: (A) the eighteen-month anniversary
of the Termination Date; (B) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (C) the date on
which the Executive receives or becomes eligible to receive substantially similar coverage from another employer. Notwithstanding the
foregoing, if the Company’s making payments under this Section 4(B)(v) would violate the nondiscrimination rules applicable to non-grandfathered
plans, or result in the imposition of penalties under the Patient Protection and Affordable Care Act of 2010 and the related regulations
and guidance promulgated thereunder (“PPACA”), the parties agree to reform this Section 4(B)(v) in a manner as is necessary
to comply with the PPACA.

 

Any compensation payable
pursuant to clause (i), (iii) and (iv) of this paragraph (B) shall be paid promptly after the Termination Date. Any amounts payable pursuant
to clause (ii) and (v) of this paragraph (B) shall be paid ratably for a period of twenty-four (24) months following termination of employment
as if it were salary, payable in accordance with the Company’s normal payroll practices, provided, however, that the initial installment
will begin on the 60th day following the Termination Date and will include the payments that would otherwise have been made
during such sixty (60) day period; provided that, to the extent necessary to prevent the Executive from being subject to adverse tax
consequences under Section 409A of the Internal Revenue Code and the regulations promulgated thereunder (“Section 409A”),
the first six (6) months of the continued Severance Payment shall not be paid until, and shall be paid in a single sum payment on, the
first day after the six (6) month anniversary of the Termination Date, with the remaining monthly payments to begin on the first day
of the seventh month following the Termination Date. At the end of the period during which the Company is paying the Executive’s
premiums for medical and dental coverage, the Executive and any eligible family members may elect COBRA continuation coverage at his
own expense for the remainder, if any, of the required COBRA period. For the purposes hereof, if the Company elects not to extend the
Term pursuant to Section 1 above, the Executive’s employment will be deemed to have been terminated by the Company without Cause.

 

 

 

    	 	3	 

     

    

 

In order
to receive any payments or benefits under clauses (ii), (iii), (iv) and (v) of this paragraph (B), the Executive must execute and deliver
to the Company a release provided by the Company in substantially the form of Exhibit A annexed hereto and such release must become irrevocable
on or before the 60th day following the Termination Date.

 

As of the
Termination Date, except as set forth herein, the Executive shall not be entitled to any further payments or benefits from the Company.

 

“Good
Reason” shall mean the occurrence of any of the following events without the Executive’s express written consent: (i)
a material diminution in the Executive’s position, title, authority, duties, working conditions or responsibilities, except for
a salary reduction implemented as part of across the board salary reductions affecting all similarly situated executives; (ii) a material
breach of this Agreement by the Company; or (iii) in connection with a Change of Control, the failure or refusal by the successor or acquiring
company (or parent thereof) to expressly assume the obligations of the Company under this Agreement. The Executive must provide written
notice to the Company of the existence of the condition constituting the Good Reason within thirty (30) days of the Executive’s
having actual knowledge of the existence of the condition and, if the condition is curable, the Company will then have fifteen (15) days
from receipt of such notice during which the Company may remedy the condition and not be required to pay the amounts set forth in this
Section 4(B). If full cure is made by the Company within such fifteen (15) day cure period, Good Reason shall be deemed not to have occurred
and the Executive’s employment will be deemed to have continued under and subject to the provisions of this Agreement.

 

(C)          
Termination on Disability or Death. In the event that the employment of the Executive terminates prior to the end of the
Term by reason of Disability (as defined below), the Executive shall be entitled to the payments set forth in clauses (i), (ii), and
(vi) of Section 4(B) including payments under the Company’s long term disability insurance plan to the extent provided for therein.
The Company may terminate the Executive’s employment by reason of “Disability” if (and only if) the Executive is absent
from work for at least one-hundred eighty (180) consecutive days or for one-hundred eighty (180) days (whether or not consecutive) in
any calendar year by reason of a physical or mental illness or injury. In the event that the employment of the Executive terminates before
the end of the Term by reason of death, the amounts set forth in clauses (i), (iii), (iv) and (v) of Section 4(B) shall be paid to his
estate and the death benefit under the Company’s life insurance program, if any, shall be paid to his designated beneficiary, or
estate in the absence of designated beneficiary.

 

In addition,
if the Executive’s employment under this Agreement is terminated prior to the end of the Term by reason of Disability or death,
any unvested equity compensation and any additional option awards that are granted to the Executive shall become immediately vested and
non-forfeitable on the Termination Date and shall be transferable or exercisable for the remainder of their terms.

 

(D)          
Change of Control. If the Executive’s employment under this Agreement is terminated prior to the end of the Term by
the Company without Cause or by the Executive for Good Reason within two (2) years after a Change in Control or within six (6) months
prior to a Change in Control, the Executive will be entitled to the payments and benefits set forth in Section 4(B) in a single sum cash
payment on the 60th day following his termination of employment, and otherwise subject to the terms thereof (including, without
limitation, acceleration of vesting and continuing exercisability of any equity awards). Notwithstanding the foregoing, if a Change of
Control occurs and any Company equity awards (“Transaction Date Equity Awards”) are not assumed or converted into comparable
awards with respect to stock of the acquiring or successor company (or parent thereof), then, immediately prior to the Change of Control,
each such Transaction Date Equity Award, whether or not previously vested, shall be converted into the right to receive cash or, at the
election of the Executive, consideration in a form that is pari passu with the form of the consideration payable to the Company’s
stockholders in exchange for their shares, in an amount or having a value equal to the product of (i) the per share fair market value
of the Company’s Common Stock (based upon the consideration payable to the Company’s stockholders), less, if applicable, the
per share exercise price under such Transaction Date Equity Award, multiplied by (ii) the number of shares of Common Stock covered by
such Transaction Date Equity Award (such product being referred to as the “Award Cash-Out Amount”). The Award Cash-Out
Amount with respect to each Transaction Date Equity Award will be paid or settled at the time of or promptly (but not more than ten (10)
days) following the occurrence of the Change of Control; provided, however, that, for the avoidance of doubt, if the Company’s stockholders
receive deferred and/or contingent consideration, then the Executive will be entitled to receive such consideration as if the shares of
Common Stock covered by his Transaction Date Equity Awards had been outstanding at the time of the Change of Control.

 

 

 

    	 	4	 

     

    

 

“Change in Control” means any of the
following:

 

(i)            
any one person or more than one person acting as a group directly or indirectly acquires ownership of shares of the Company that,
together with the shares of the Company held by such person or group, constitutes more than thirty percent (30%) of the total fair market
value or total voting power of the shares of the Company; provided, however, that if any one person or more than one person acting as
a group is considered to own more than thirty percent (30%) of the total fair market value or total voting power of the shares of the
Company, the acquisition of additional shares by the same person or persons shall not constitute a Change of Control under this clause
(i). An increase in the percentage of shares of the Company owned by any one person or persons acting as a group as a result of a transaction
in which the Company acquires its own shares in exchange for property will be treated as an acquisition of shares of the Company by such
person or persons for purposes of this clause (i);

 

(ii)           
a majority of the members of the Company’s Board are replaced during any twelve (12) month period by directors whose appointment
or election is not endorsed by a majority of the Company’s Board prior to the date of such appointment or election; or

 

 (iii)           the sale of all or substantially all of the Company’s assets.

 

Notwithstanding
the foregoing, a Change in Control shall not occur unless such transaction constitutes a change in the ownership of the Company, a change
in effective control of the Company or a change in the ownership of a substantial portion of the Company's assets under Section 409A.

 

(E)           
Section 280G. In the event that it is determined that any payments or benefits provided under this Agreement, together with
any payments or benefits to be provided under any other plan, program, arrangement or agreement, would constitute parachute payments within
the meaning of Section 280G of the Code and would, but for this Section 4(E) be subject to the excise tax imposed under Section 4999 of
the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect
to such taxes (“Excise Tax”), then the amounts of any such payments or benefits under this Agreement and such other
arrangements shall be either (a) paid in full or (b) reduced to the minimum extent necessary to ensure that no portion of the payments
or benefits is subject to the Excise Tax, whichever of the foregoing (a) or (b) results in the Executive’s receipt on an after-tax
basis of the greatest amount of payments and benefits after taking into account the applicable federal, state, local and foreign income,
employment and excise taxes (including the Excise Tax). The Company shall cooperate in good faith with the Executive in making such determination,
including but not limited to providing the Executive with an estimate of any parachute payments as soon as reasonably practicable prior
to an event constituting a change in the ownership or effective control of the Company or in the ownership of a substantial portion of
the assets of the Company (within the meaning of Section 280G(b)(2)(A) of the Code). Any such reduction pursuant to this Section 4(E)
shall be made in a manner that results in the greatest economic benefit for the Executive and is consistent with the requirements of Section
409A. Any determination required under this Section 4(E) shall be made in writing in good faith by a nationally recognized public accounting
firm selected by the Company. The Company and the Executive shall provide the accounting firm with such information and documents as the
accounting firm may reasonably request in order to make a determination under this Section 4(E).

 

(F)           
No Mitigation. In the event of any termination of the employment of the Executive hereunder prior to the end of the Term,
the Executive shall be under no obligation to seek other employment, and there shall be no offset against any amounts due him on account
of any remuneration attributable to any subsequent employment that he may obtain.

 

 

 

    	 	5	 

     

    

 

5.     CONFIDENTIALITY.
The Executive recognizes and acknowledges that the continued success of the Company and its affiliates (“Company Group”)
depends upon the use and protection of a large body of confidential and proprietary information and that the Executive will have access
to certain Confidential Information (as defined below) of the Company Group, and that such Confidential Information constitutes valuable,
special and unique property of the Company Group. “Confidential Information” will be interpreted to include, without limitation,
with respect to the Company Group: (i) inventions, technology, know-how, documentation, devices, methods, algorithms, processes, designs,
manuals, analyses, improvements, research and development, non-public scientific and medical data and methods, clinical plans, trials
and strategies, technical procedures and products; (ii) computer software (including operating systems, applications and program listings);
(iii) identities and lists of, individual requirements of, specific contractual arrangements with and information about, employees, customers,
vendors, distributors, independent contractors or other business relations and their confidential information; (iv) existing or future
products and services (including those under development) and related costs and pricing structures; (v) financial data, accounting and
business methods and practices, marketing information and business strategies and operations; (vi) non-public information concerning
legal and professional dealings, real property, tangible property and investment activities, and (vii) similar and related confidential
information and sensitive information and trade secrets. “Confidential Information” shall not include information that: (i)
was in the possession of or known by Executive free of any obligation prior to disclosure by the Company; (ii) is or becomes generally
known to the public through disclosure in a printed publication (without breach of any of the Executive’s obligations hereunder);
(iii) was acquired by the Executive from a third party who independently generated such information; or (iv) is disclosed pursuant to
judicial or governmental order, provided that the Executive promptly notifies the Company so that the Company has an adequate opportunity
to respond to such order.

 

The Executive
shall, during and after his employment by the Company and except in connection with performing services on behalf of (or for the benefit
of) the Company or the Company Group, keep secret and retain in the strictest confidence all Confidential Information and shall not disclose
such information to any person, entity or any federal, state or local agency or authority, except as may be required by law. Notwithstanding
the foregoing, nothing contained herein shall prohibit the Executive from filing a charge with, reporting possible violations of federal
law or regulation to, participating in any investigation by, or cooperating with any governmental agency or entity or making other disclosures
that are protected under the whistleblower provisions of applicable law or regulation.

 

Upon termination of his employment
with the Company, the Executive shall return to the Company all confidential, proprietary and non-public materials, and any other property
of the Company, in his possession. The personal property of the Executive, including documents relating to his benefits, compensation,
tax liabilities, personal obligations (e.g., restrictive covenants) and the like, shall not be subject to return pursuant to the preceding
sentence.

 

6.     
NON-COMPETE; NONSOLICITATION. The Executive understands and acknowledges that the services he provides to the Company are unique
and extraordinary. The Executive further understands and acknowledges that the Company’s ability to reserve these services for the
exclusive use of the Company is of great competitive importance and commercial value to the Company. The Executive agrees that during
his employment by the Company and for twenty-four (24) months thereafter, he shall not, directly or indirectly, engage or be interested
in (as owner, partner, stockholder, employee, director, officer, agent, fiduciary, consultant or otherwise), with or without compensation,
any line of business in which the Company or its affiliates is actively engaged (or, in the case of cessation of employment, in which
the Company or any of its consolidated subsidiaries is then engaged at the time of such cessation). The Executive further agrees that
for twenty-four (24) months following the Termination Date, the Executive will not:

 

(A)      
directly or indirectly, contact, solicit, or accept if offered to him, or direct any person, firm, corporation, association or
other entity to contact, solicit or accept if offered, any of the Company’s customers, prospective customers, or suppliers for the
purpose of providing any products and/or services that are the same as or similar to the specific products and services provided by the
Company to its customers during the Term; or

 

(B)       
solicit or accept if offered to the Executive, with or without solicitation, on his behalf or on behalf of any other person, the
services of any person who is then a current employee of the Company (or was an employee during the six-month period preceding such solicitation),
to terminate employment or an engagement with the Company, nor hire or agree to hire any such current or former employee into employment
with the Executive or any company, individual or other entity; provided, however, that this subpart (B) will not apply to applications
for employment from any current or former employee of the Company in response to a general solicitation that is not directed at any such
current or former employee; and provided further that this subpart (ii) shall not be deemed to preclude any future employer of the Executive
from hiring any such current or former employee of the Company without the input or participation by the Executive.

 

(C)       
The Executive further represents that the Executive’s fulfillment of the obligations set forth in this Section shall not
cause the Executive any substantial economic hardship or render the Executive unemployable within the industry either during or after
the Restricted Period.

 

 

 

    	 	6	 

     

    

 

7.     
NONDISPARAGEMENT. The Executive agrees not to, either during his employment with the Company or after his employment with
the Company has terminated, make or condone any negative, disparaging, denigrating, or derogatory remarks, either orally or in writing,
about the Company, its predecessors, successors and assigns, and any of its or their directors, officers, employees, affiliates or any
shareholder, or members of their respective families, including, without limitation, remarks that relate to their respective business
operations, policies or practices, and remarks that may be considered to be detrimental to any of their business, professional, or personal
reputations. Nothing herein shall be deemed to preclude the Executive from testifying truthfully under oath if he is required or compelled
by law to testify in any judicial action or before any government authority or agency or from making any other legally required truthful
statements or disclosures.

 

8.   
COOPERATION. Following any termination of employment, the Executive shall cooperate with the Company in the winding up of pending
work on behalf of the Company and the orderly transfer of work to other employees. The Executive shall also cooperate with the Company
in the defense of any action brought by any third party against the Company that relates to the Executive’s employment by the Company.
In the event that the Executive is subpoenaed in connection with any litigation or investigation relating to the Company or its affiliates,
the Executive will promptly notify the Company. For the avoidance of doubt, the Executive will be reimbursed for the Executive’s
reasonable costs and expenses incurred by the Executive in complying with the terms of this Section 8. The Executive acknowledges that
the Executive’s agreement to provide cooperation as set forth in this Section 8 is material to the Company.

 

9.     
REMEDY FOR BREACH AND MODIFICATION. The Executive acknowledges that the provisions of this Agreement are reasonable and necessary
for the protection of the Company and that the Company may be irreparably damaged if these provisions are not specifically enforced. Accordingly,
the Executive agrees that, in addition to any other relief or remedies available to the Company, the Company shall be entitled to obtain
appropriate temporary, preliminary and permanent injunctive or other equitable relief for the purposes of restraining the Executive from
any actual or threatened breach of or otherwise enforcing these provisions and no bond or security will be required in connection therewith.
In addition, notwithstanding any provision in this Agreement to the contrary, if the Executive breaches any of the provisions of Sections
5, 6 or 7 of this Agreement at any time and such breach is either (x) willful and not inconsequential or (y) in a material respect and
not cured promptly after notice from the Company, he shall not thereafter be entitled to any payments or benefits under this Agreement,
and any option award (whether or not previously vested) will immediately terminate and the options granted pursuant thereto will no longer
be exercisable.

 

10. 
SEVERABILITY; BLUE PENCIL. If any provision of this Agreement is deemed invalid or unenforceable, such provision shall be deemed
modified and limited to the extent necessary to make it valid and enforceable. The Executive and the Company agree that the covenants
contained in Sections 5, 6 and 7 are reasonable covenants under the circumstances and further agree that if, in the opinion of any court
of competent jurisdiction such covenants are not reasonable in any respect, such court shall have the right, power and authority to excise
or modify such provision or provisions of these covenants to such narrower scope as it determines to be enforceable and to enforce the
remainder of these covenants as so amended. The Executive and the Company further agree that if any provision of this Agreement is determined
to be unenforceable for any reason, and such provision cannot be reformed by the court as anticipated above, such provision shall be deemed
separate and severable and the unenforceability of any such provision shall not invalidate or render unenforceable any of the remaining
provisions hereof.

 

11.    
COUNTERPARTS; FACSIMILES. This Agreement may be executed in two (2) or more counterparts, each of which shall be considered
an original, but all of which together shall constitute the same instrument. Signatures delivered by facsimile or email shall be effective
for all purposes.

 

 

 

    	 	7	 

     

    

 

12. GOVERNING LAW; JURISDICTION.

 

(A)      
As a corporation incorporated in Nevada itself, the Company has an interest in having Nevada law applied to contracts with its
employees, as well as disputes with them. Applying Nevada law in this fashion affords the parties predictability as to the law to be applied,
as well as uniformity across the Company’s workforce. Consequently, this Agreement and the legal relations thus created between
the Parties shall be governed by, and construed and interpreted in accordance with its express terms, and otherwise in accordance with
the laws of the State of Nevada, without regard to its choice of laws or conflicts of laws principles (whether of the State of Nevada
or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the State of Nevada.

 

(B)       
Either Party may seek to enforce this Agreement in the courts of the State of Nevada. Each Party hereby consents to the non-exclusive
jurisdiction of such courts (and the appropriate appellate courts) and waives any objection to lack of jurisdiction or improper or inconvenient
venue of any such court. Process in any action or proceeding referred to in the preceding sentence may be served on either Party anywhere
in the world, whether within or without the State of Nevada. By signing below, the Executive acknowledges that the Company has advised
the Executive to obtain legal counsel in negotiating the terms of this Agreement including without limitation this Section 12.

 

13. 
NOTICES. Any notice or other communication made or given in connection with this Agreement may be given by counsel, shall be
in writing, and, if to a Party, shall be deemed to have been duly given when: (i) delivered to the appropriate address by hand or by nationally
recognized overnight courier service (costs prepaid); (ii) sent by electronic mail or facsimile with confirmation of transmission by the
transmitting equipment; or (iii) received or rejected by the addressee, if sent by certified mail, return receipt requested, in each case
to a Party at his or its address or facsimile number set forth below or at such other address or facsimile number as a Party may specify
by notice to the other Party:

 

To the Executive:

 

25422 Trabuco Road, Suite 105

Lake Forest, California 92630

Email: kwaggoner@PharmaCyte.com

Fax No.: (917) 595-2851

 

 

To the Company:

 

3960 Howard Hughes Parkway, Suite 500

Las Vegas, Nevada
89169

Attention: Carlos A. Trujillo

Chief Financial Officer

Email: ctrujillo@Pharmacyte.com

Fax No.: (917) 595-2851

 

14.   
ENTIRE AGREEMENT; AMENDMENT. This Agreement supersedes all prior agreements between the Parties with respect to its subject
matter, including, without limitation, the Prior Executive Agreement, and cannot be changed or terminated orally. Any amendment thereof
must be in writing and signed by the Parties.

 

 

 

    	 	8	 

     

    

 

15.  
WAIVER. The failure of any Party or person to insist upon strict adherence to any term of this Agreement (including all attachments)
on any occasion shall not be considered a waiver or deprive that Party or person of the right thereafter to insist upon strict adherence
to that term or any other term of this Agreement (including all attachments). Any waiver must be in writing and must specifically identify
the provision(s) of this Agreement (including all attachments) being affected.

 

16.  
END OF TERM. The provisions of Sections 4, 5, 6, 7, 8, 11, 12, 13 and 14 shall continue after the end of the Term.

 

17. 
ASSIGNMENT. Except as otherwise provided in this Section 17, this Agreement shall inure to the benefit of and be binding upon
the Parties and their respective heirs, representatives, successors and assigns. This Agreement shall not be assignable by the Executive,
and shall be assignable by the Company only to any corporation or other entity that succeeds to all, or substantially all, of the Company’s
business or assets, and that expressly assumes (or assumes by operation of law in any merger or consolidation) the Company’s obligations
hereunder; provided, however, that no such assignment shall invalidate or negate the rights of the Executive pursuant to the provisions
hereof, including, without limitation, any such rights relating to a Change of Control. In any such event, the term “Company,”
as used herein shall mean the Company, as defined above, and any such successor or assignee. In the event of the Executive’s death
or a judicial determination of his incapacity, references in this Agreement (including its attachments) to the “Executive”
shall be deemed to include, as appropriate, his estate, heirs and/or legal representatives.

 

18.   
CODES. The Board has adopted a Code of Business Conduct and Ethics. The Executive is expected to require compliance with those
codes by the Company’s employees and to comply himself.

 

19.  
DEDUCTIONS. The Company may deduct from the compensation described herein any applicable Federal, state and/or city withholding
taxes, any applicable social security contributions, and any other amounts which may be required to be deducted or withheld by the Company
pursuant to any Federal, state or city laws, rules or regulations or any election he shall have made.

 

 20. SECTION 409A. Anything in this Agreement to the contrary notwithstanding:

 

	 	(21)	It
is intended that any amounts payable under this Agreement will either be exempt from or comply with Section 409A and all regulations,
guidance and other interpretive authority issued thereunder so as not to subject the Executive to payment of any additional tax penalty
or interest imposed under Section 409A, and this Agreement will be interpreted on a basis consistent with such intent. References to Termination
Date or termination of employment herein mean a termination of employment that constitutes a “separation from service” within
the meaning of Section 409A.

 

(B) To the
extent that the reimbursement of any expenses or the provision of any in- kind benefits under this Agreement is subject to Section 409A:
(i) the amount of such expenses eligible for reimbursement, or in-kind benefits to be provided during any one (1) calendar year shall
not affect the amount of such expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year (provided
that this clause (i) will not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section
105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect); (ii) reimbursement of
any such expense shall be made by no later than December 31 of the year following the calendar year in which such expense is incurred;
and (iii) the Executive’s right to receive such reimbursements or in-kind benefits shall not be subject to liquidation or exchange
for another benefit.

 

(C) Whenever
payments under this Agreement are to be made in installments, each such installment shall be deemed to be a separate payment for purposes
of Section 409A. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date
of payment within the specified period shall be within the sole discretion of the Company.

 

 

 

    	 	9	 

     

    

 

(D) To the extent any amount
payable to the Executive is subject to his entering into a release of claims with the Company and any such amount is a deferral of compensation
under Section 409A and which amount could be payable to the Executive in either of two (2) taxable years, and the timing of such payment
is not subject to terms and conditions under another plan, program or agreement of the Company that otherwise satisfies Section 409A,
such payments shall be made or commence, as applicable, on January 15 (or any later date that is not earlier than eight (8) days after
the date that the release becomes irrevocable) of such later taxable year and shall include all payments that otherwise would have been
made before such date.

 

21.  
CAPTIONS. The captions in this Agreement are for convenience of reference only and shall not be given any effect in the interpretation
of this Agreement.

 

 

[Balance of this page left
blank intentionally]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF, the Executive
and the Company have signed this Agreement as of the date first set forth above.

 

 

 

	 	PHARMACYTE BIOTECH, INC
	 	 
	 	By:	/s/ Raymond C.F.Tong                      
	 	 	Name: Raymond C.F. Tong
	 	 	Title: Director and Chairman of the 
	 	 	Compensation Committee
	 	 
	 	 
	 	

THE EXECUTIVE

	 	 
	 	 
	 	By:	/s/ Kenneth L. Waggoner               
	 	 
	 	 

 

 

.

 

 

		By:	

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	11	 

     

    

 

Exhibit A

 

GENERAL RELEASE

 

		1.	GENERAL RELEASE OF ALL CLAIMS

 

The undersigned
individual (“Executive”) hereby irrevocably releases and forever discharges any and all known and unknown liabilities,
debts, obligations, causes of action, demands, covenants, contracts, liens, controversies and any other claim of whatsoever kind or nature
that the Executive ever had, now has or may have in the future against PharmaCyte Biotech, Inc. (“Company”), its shareholders,
subsidiaries, affiliates, successors, assigns, officers, directors, attorneys, fiduciaries, representatives, employees, licensees, agents
and assigns (“Releasees”), to the extent arising out of or related to the performance of any services to or on behalf
of the Company or the termination of those services and, other than claims for payments, benefits or entitlements preserved by Section
4 and claims for indemnification, advancement of expenses or coverage under the Company’s directors and officers liability insurance,
of the Amended and Restated Executive Compensation Agreement dated as of April , 2022, between the Company and the Executive (“Employment
Agreement”), including without limitation: (i) any such claims arising out of or related to any federal, state and/or local
labor or civil rights laws including, without limitation, the federal Civil Rights Acts of 1866, 1871, 1964, the Equal Pay Act, the Older
Workers Benefit Protection Act, the Rehabilitation Act, the Jury Systems Improvement Act, the Uniformed Services Employment and Reemployment
Rights Act, the Vietnam Era Veterans Readjustment Assistance Act, the National Labor Relations Act, the Worker Adjustment and Retraining
Notification Act, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974, the Age Discrimination
in Employment Act, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act of 1938, the California Fair Employment
and Housing Act, the California Labor Code, the California Constitution, the California Family Rights Act, the Nevada Fair Employment
Practices Act, the Maryland Fair Employment Practices Act, the Health Care Worker Whistleblower Protection Act, the Maryland False Claims
Act, the Maryland Parental Leave Act, the Maryland Health Working Families Act, the Maryland Wage and Hour Law, the Maryland Wage Payment
and Collection Law and the Maryland Equal Pay for Equal Work Law, all including any amendments and their respective implementing regulations;
(ii) any and all other such claims arising out of or related to any contract, any and all other federal, state or local constitutions,
statutes, rules, regulations or executive orders; or (iii) any and all such claims arising from any common law right of any kind whatsoever,
including, without limitation, any claims for any kind of tortious conduct, promissory or equitable estoppel, defamation, breach of the
Company’s policies, rules, regulations, handbooks or manuals, breach of express or implied contract or covenants of good faith,
wrongful discharge or dismissal, and/or failure to pay, in whole or part, any compensation of any kind whatsoever (collectively, “Executive’s
Claims”).

 

The Executive
is not releasing any unemployment claims, workers’ compensation claims, right to COBRA benefits, or any other claim which as a matter
of law. To the extent any local, state or federal administrative agency files any claims on the Executive’s behalf arising out of
or related to the Executive’s employment, the Executive waives, to the fullest extent permitted by law, to any right to any monetary
or other recovery as a result of such action, with the exception of monetary recovery on whistleblower awards.

 

Execution
of this Release by the Executive operates as a complete bar and defense against any and all of the Executive’s Claims against the
Company and/or the other Releasees. If the Executive should hereafter assert any Executive’s Claims in any action or proceeding
against the Company or any of the Releasees, as applicable, in any forum, this Release may be raised as and shall constitute a complete
bar to any such action or proceeding and the Company and/or the Releasees shall be entitled to recover from the Executive all costs incurred,
including attorneys’ fees, in defending against any such Executive’s Claims.

 

 

 

    	 	12	 

     

    

 

For the purpose
of implementing a full and complete release, the Executive expressly acknowledges that the release given in this Agreement is intended
to include, without limitation, claims that Executive did not know or suspect to exist in the Executive’s favor at the time of execution
of the Agreement, regardless of whether the knowledge of such claims, or the facts upon which they might be based, would materially have
affected the settlement in this matter, and that the consideration provided under this Agreement is also for the release of those claims
and contemplates extinguishment of any such unknown claims. The Executive further waives and relinquishes any rights and benefits which
he has or may have under California Civil Code § 1542 to the fullest extent that he may lawfully waive all such rights and benefits
pertaining to the subject matter of this Release. Civil Code § 1542 provides that a general release does not extend to claims which
the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially
affected his settlement with the debtor. The Executive acknowledges that he is aware that he may later discover facts in addition to or
different from those which he now knows or believes to be true with respect to the subject matter of this Release, but it is his intention
to fully and finally forever settle and release any and all claims, matters, disputes, and differences, known or unknown, suspected and
unsuspected, which now exist, may later exist or may previously have existed between the parties to the extent set forth in the first
paragraph hereof, and that in furtherance of this intention this Release shall be and remain in effect as a full and complete general
release to the extent set forth in the first paragraph herein, notwithstanding discovery or existence of any such additional or different
facts.

 

		2.	OPPORTUNITY FOR REVIEW

 

This Agreement
constitutes a voluntary waiver and release of any and all rights and claims Employee may have under the Age Discrimination in Employment
Act (ADEA). The Executive acknowledges that he has had a reasonable opportunity to review and consider the terms of this Release for a
period of at least twenty-one (21) days, that the Company has advised the Executive, in writing, to consult an attorney prior to signing
this Agreement and that the Executive has had the opportunity to receive counsel regarding his/ her respective rights, obligations and
liabilities under this Release and that to the extent that the Executive has taken less than twenty-one (21) days to consider this Release,
the Executive acknowledges that he has had sufficient time to consider this Release and to consult with counsel and that he does not desire
additional time to consider this Release. As long as the Executive signs and delivers this Release within such twenty- one (21) daytime
period, he will have seven (7) days after such delivery to revoke his decision by delivering written notice of such revocation to the
Company to [Physical or Email Address]. If the Executive does not revoke his decision during that seven (7) day period, then this Release
shall become effective on the eighth (8th) day after being delivered by the Executive.

 

		3.	COVENANT NOT TO SUE.

 

To the maximum
extent permitted by law, the Executive covenants not to sue or to institute or cause to be initiated, or maintain, any action in federal,
state or local agency or court against any of the Releasees, including, but not limited to, any of the claims released above.

 

		4.	BINDING EFFECT.

 

 

This Release is binding on the Executive’s heirs and
personal representative.

 

		5.	NO ASSIGNMENT OF CLAIMS

 

The Executive
represents and warrants that the Executive has not assigned or otherwise transferred or subrogated, or purported to assign, transfer,
or subrogate, to any person or entity, any claim or portion thereof or interest therein that the Executive may have against the Releasees.

 

 

 

    	 	13	 

     

    

 

		6.	GOVERNING LAW; MISCELLANEOUS

 

The provisions
of Sections 9, 10, 11, 12 and 14 of the Employment Agreement shall be deemed incorporated into this Release as if fully set forth herein.
Any claim or dispute arising under or relating to this Release, or the breach, termination or validity of this Release, shall be subject
to Section 12 of the Employment Agreement.

 

 

 

	 	PHARMACYTE BIOTECH, INC
	 	 
	 	By:	 _______________________________
	 	 	Name: Raymond C.F. Tong
	 	 	Title: Director and Chairman of the 
	 	 	Compensation Committee
	 	 
	 	 
	 	

THE EXECUTIVE

	 	 
	 	 
	 	By:	_______________________________
	 	 
	 	 

 

 

 

 

 

 

 

 

 

    	 	14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]